Latest News

Mecasermin treatment for Rett Syndrome is safe, well-tolerated

A Phase 1 clinical trial using mecasermin [recombinant human insulin-like growth factor 1 (IGF-1)] has been completed for Rett Syndrome research, showing proof-of-principle that treatments like IGF-1 which are based on the neurobiology of Rett syndrome, are possible.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Pathological gambling is associated with altered opioid system in the brain: Reduced feeling of euphoria when compared to healthy volunteers

  • Why depression and aging are linked to increased disease risk

  • Birth season affects your mood in later life, new research suggests

  • Highly Connected CEOs More Likely to Broker Mergers and Acquisitions That Harm Firms

  • Irritable bowel syndrome: Males report more social stress than females

  • New test to help brain injury victims recover

  • Panic attacks associated with fear of bright daylight

  • Fish intake associated with boost to antidepressant response

  • Aspirin shown to benefit schizophrenia treatment

  • American Alzheimer's plan milestones must be strengthened to meet goal by 2025, experts say

  •